Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibuprofen + G-CSF + plerixafor for stem cell mobilization in X-linked chronic granulomatous disease
2015-002356-27Phase 2Completed
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibuprofen in X-linked chronic granulomatous disease (X-CGD), sponsored by IRCCS Ospedale San Raffaele. Primary endpoint: Safety of ibuprofen + G-CSF + plerixafor mobilization regimen. Started Jul 2015; status: completed.
02
Drugs
ibuprofen
03
Conditions
X-linked chronic granulomatous disease (X-CGD)
Beyond the preview
Go deeper on 2015-002356-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002356-27.